BioSenic S.A. (EBR:BIOS)

Market Cap	1.50M
Revenue (ttm)	102.00K
Net Income (ttm)	-4.77M
Shares Out	652.86M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,330,732
Average Volume	1,889,686
Open	0.0023
Previous Close	0.0023
Day's Range	0.0023 - 0.0025
52-Week Range	0.0012 - 0.0155
Beta	-2.43
RSI	42.38
Earnings Date	Oct 27, 2025

About BioSenic

BioSenic S.A., a biotechnology company, develops cell therapy products and treatments for autoimmune and inflammatory diseases in Belgium and France. The company’s technologies include arsenic trioxide (ATO) and oral arsenic trioxide (OATO) platforms. It also provides medicinal products, including ArsciMed, an intravenous drug to treat autoimmune diseases. In addition, the company develops ArsciCor, an oral medication in Phase III clinical trial and for the treatment for chronic graft-versus-host disease; JTA-004, an intra-articular injectable ...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: François Rieger
• Employees: 7
• Stock Exchange: Euronext Brussels
• Ticker Symbol: BIOS

Financial Performance

In 2024, BioSenic's revenue was 102,000, a decrease of -69.64% compared to the previous year's 336,000. Losses were -4.77 million, -83.43% less than in 2023.